aav8 encoding kcmf1 specific shrna (Obio Technology Corp Ltd)
86
Structured Review
Obio Technology Corp Ltd
aav8 encoding kcmf1 specific shrna
Aav8 Encoding Kcmf1 Specific Shrna, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav8+encoding+kcmf1+specific+shrna/encoding+gfplc3b+lentiviral+mcherry+plasmid/pm42162901-70-14-31
Average 86 stars, based on 1 article reviews
Aav8 Encoding Kcmf1 Specific Shrna, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav8+encoding+kcmf1+specific+shrna/encoding+gfplc3b+lentiviral+mcherry+plasmid/pm42162901-70-14-31
Average 86 stars, based on 1 article reviews
aav8 encoding kcmf1 specific shrna - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Knockdown:Article Title: KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα. Article Snippet: Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks effective pharmacotherapy.. Although AMP-activated protein kinase (AMPK) is a central metabolic regulator with hepatoprotective effects, the upstream mechanisms governing its degradation in MASLD remain poorly defined.. Here, we identify potassium channel modulatory factor 1 (KCMF1) as a previously unrecognized E3 ubiquitin ligase targeting AMPKα and investigate its role in MASLD pathogenesis. Injection:Article Title: KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα. Article Snippet: Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks effective pharmacotherapy.. Although AMP-activated protein kinase (AMPK) is a central metabolic regulator with hepatoprotective effects, the upstream mechanisms governing its degradation in MASLD remain poorly defined.. Here, we identify potassium channel modulatory factor 1 (KCMF1) as a previously unrecognized E3 ubiquitin ligase targeting AMPKα and investigate its role in MASLD pathogenesis. shRNA:Article Title: KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα. Article Snippet: Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks effective pharmacotherapy.. Although AMP-activated protein kinase (AMPK) is a central metabolic regulator with hepatoprotective effects, the upstream mechanisms governing its degradation in MASLD remain poorly defined.. Here, we identify potassium channel modulatory factor 1 (KCMF1) as a previously unrecognized E3 ubiquitin ligase targeting AMPKα and investigate its role in MASLD pathogenesis. Control:Article Title: KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα. Article Snippet: Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks effective pharmacotherapy.. Although AMP-activated protein kinase (AMPK) is a central metabolic regulator with hepatoprotective effects, the upstream mechanisms governing its degradation in MASLD remain poorly defined.. Here, we identify potassium channel modulatory factor 1 (KCMF1) as a previously unrecognized E3 ubiquitin ligase targeting AMPKα and investigate its role in MASLD pathogenesis. |